2 results
Search Results
Now showing 1 - 2 of 2
Book Part JAK Inhibitors/Drug Interactions(Springer Science+Business Media, 2025) Demirci Saadet, E.JAK inhibitors are a group of drugs that can affect the signaling of various cytokines simultaneously. The number of indications in dermatology has been increasing in recent years. JAK inhibitors are largely metabolized by the liver. Therefore, drug–drug interactions may occur when used with cytochrome P450 and CYP2C19 inhibitors or inducers, and drug dosages should be adjusted or not used together. In addition, OAT-3 inhibitors, which are known to play a role in renal elimination, interact with some JAK inhibitors, and dose adjustment is recommended. During treatment, drug–drug interactions should be reviewed in combination with JAK inhibitors and other drugs. © 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.Book Part Citation - Scopus: 1Safety, Toxicity Profile and Side Effects(Springer Science+Business Media, 2025) Demirci Saadet, E.; Türsen, B.Since Janus kinases mediate the effects of numerous inflammatory cytokines, various side effects are observed during treatment with JAK inhibitors that inhibit these kinases. Infections are the most common side effects. The development of malignancy, venous thromboembolism, major cardiovascular adverse events, nausea, acne, and various laboratory abnormalities has also been observed with the use of JAK inhibitors. With the long-term use of JAK inhibitors, their safety, toxicity and side effect profiles are better understood. © 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.
